Developer docs
API playgroundTry for free, no card

Search company profiles

Curi Bio

Full company profile

uuid0000ikc

Namestring
Curi Bio
Legal namestring
Curi Bio, Inc.
Websiteurl
curibio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Curi Bio (formerly NanoSurface Biomedical) is a Seattle-based preclinical biotechnology company founded in 2015 that has built the Curi Engine, an integrated platform combining human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic data analytics to support drug safety, efficacy, and potency testing for pharmaceutical R&D. The company's core technical architecture is three-pronged: proprietary human stem cell inputs (MantaReady skeletal muscle myoblasts in wild-type and isogenic DMD lines, ComboMat-matured hiPSC cardiomyocytes using a proprietary microRNA cocktail, plus Celogics iPSC-derived cell products); a portfolio of biosystem instruments (Mantarray for label-free, non-optical, magnetic 3D tissue contractility measurement of up to 24 parallel tissues, Nautilai/Nautilai Plus for voltage and calcium imaging, Stingray for tissue stimulation and maturation, Cytostretcher for biomimetic mechanical strain, and NanoSurface 96/384-well plates for structural maturation); and the Pulse cloud analytics platform with PhenoLearn (deep-learning phenotype modeling) and PhenoTox (FDA-validated predictive safety pharmacology) modules acquired from Dana Solutions.

Curi Bio's business model is anchored in enterprise sales to global pharmaceutical and biopharmaceutical R&D, with the company publicly stating that all of the top-10 global pharmaceutical companies are among its clients, customers, or partners. Revenue is generated through instrument and hardware sales (Mantarray, Nautilai, Cytostretcher), recurring consumables (NanoSurface plates, MantaReady cells and media, Celogics cardiomyocytes), fee-for-service Curi Engine contracts for compound profiling, assay/model development, and AI-enabled phenotypic screening, and subscription-based Pulse analytics. All pricing is quote-based and not publicly disclosed; commercial motion is sales-led with 'Request a Quote' CTAs, supplemented by strategic co-development and channel partnerships.

Curi Bio has executed a multi-year capital strategy combining equity ($6M Series A led by Dynamk Capital in March 2021, oversubscribed to $10M total in December 2021, and a $10M Series B led by Seoul-based DreamCIS in December 2025) with over $12M in cumulative non-dilutive NIH SBIR funding. Distribution and geographic reach are extended via the October 2021 Celogics joint venture with South Korea-based NEXEL for iPSC cell production, the January 2026 full acquisition of Quvit Bio establishing Curi Bio Co., Ltd. as an Asia-Pacific hub serving South Korea, Japan, and China, and co-commercialization partnerships with Battelle (Neuromuscular Junction assays, March 2026), Novoheart (Pulse + hvCoC integration, December 2024), and Cook MyoSite (April 2025). Proprietary technologies are protected by 19 patents, including exclusive University of Washington licenses for Mantarray and ComboMat, and the company was ranked #123 (and #18 of 70 life sciences companies) on Deloitte's 2024 Technology Fast 500.

Short descriptiontext

Curi Bio is a Seattle-based preclinical biotech founded in 2015 that provides an integrated platform combining human iPSC-derived cell models, tissue biosystems, and AI/ML analytics to support drug safety, efficacy, and potency testing for global pharmaceutical R&D customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC-derived tissue models, preclinical drug discovery, 3D engineered tissues, contractility analysis platforms, AI-enabled phenotypic screening
Industry2 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Discovery Platforms
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument & Hardware Sales
TypeHardware Sales
Description

One-time and capital sale of bioscience instruments and platforms including Mantarray, Nautilai, Nautilai Plus, Stingray, and Cytostretcher, paired with multiwell consumable plates and ongoing service contracts.

curibio.com
2Consumables & Biological Products
TypeSubscription Recurring
Description

Recurring revenue from cells, media, and plates (NanoSurface 96/384-well plates, MantaReady myoblasts, MantaReady Skeletal Muscle Media, cardiac media, metabolic media, Celogics Celo.Cardiomyocytes) sold as standalone catalog products or as kits.

curibio.com
3Curi Engine™ Custom Research Services
TypeProfessional Services
Description

Fee-for-service contracts and partnerships leveraging the Curi Engine, including compound profiling/screening, assay/model development, A.I.-enabled phenotype screening studies, and customized endpoints for pharmaceutical customers.

curibio.com
4Software / Data Analytics (Pulse)
TypeSubscription Recurring
Description

Cloud-based Pulse analytics platform offered for high-throughput waveform and video analysis of contractility datasets, with integrations to instruments like Novoheart's hvCoC; positioned as turnkey analytics pipeline.

curibio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based enterprise pricing for instruments, consumables, services, and analytics
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; all transactions routed through 'Request a Quote' / 'Contact' forms.

curibio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1Mantarray
Description

Proprietary label-free, non-optical, electromagnetic platform for parallel analysis of up to 24 3D engineered muscle tissues (EMTs) for drug discovery.

curibio.com
+11 more records
Core offering1 text field

Curi Bio develops, manufactures, and sells an integrated preclinical drug discovery platform (the Curi Engine™) that combines human iPSC-derived cell and disease models (cardiac, skeletal muscle, neuromuscular), proprietary 3D tissue biosystems (Mantarray contractility, NanoSurface plates, ComboMat maturation, Stingray, Nautilai, Cytostretcher), biological consumables (MantaReady cells and media, Celogics Celo.Cardiomyocytes, MYBPC3 HCM lines), and the Pulse™ cloud AI/ML analytics platform. The company also offers Curi Engine™ fee-for-service contract research for compound screening, assay development, and phenotypic safety/efficacy/potency studies to pharmaceutical and biotech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Selected for 2024 Deloitte Technology Fast 500 with rank #123 (#18 of 70 life sciences companies), based on percentage fiscal year revenue growth 2020–2023.
+4 more records
Product and service18 records
1Mantarray™ 3D Tissue Contractility Analysis Platform
CategoryBiosystem platform (instrument)
Description

Proprietary biosystem platform that uses a label-free, non-optical, electromagnetic measurement system to directly assess contractility of up to 24 parallel iPSC-derived 3D engineered muscle tissues simultaneously, enabling discovery, safety, and efficacy testing of new therapeutics across cardiac and skeletal muscle applications. Sold to pharmaceutical, biotech, and academic customers.

2Mantarray Mini Plates
CategoryBiosystem consumable / plates
Description

Latest addition to the 3D Engineered Tissue Ecosystem; reduces biological material requirements for 3D engineered tissues while maintaining full compatibility with Mantarray and Nautilai platforms, addressing cell sourcing challenges and enabling cost-effective higher-throughput studies.

3Nautilai™ Voltage & Calcium Imaging
CategoryBiosystem platform (instrument)
Description

Biosystem platform for voltage and calcium imaging of 3D engineered tissues, enabling fluorescence-based functional analyses of iPSC-derived cardiac and skeletal muscle constructs.

4Nautilai Plus™ 3D Tissue Contractility and Fluorescence at Scale
CategoryBiosystem platform (instrument)
Description

Scales 3D tissue contractility and fluorescence imaging capabilities, extending the Nautilai platform for higher-throughput functional analyses of engineered tissues.

5Stingray™ Stimulation and Maturation of 3D Engineered Tissues
CategoryBiosystem platform (instrument)
Description

Biosystem platform for stimulation and maturation of 3D engineered tissues, enabling electrical/mechanical conditioning to advance translational research with iPSC-derived tissues.

6NanoSurface™ Plates (96-well and 384-well)
CategorySubstrate / consumable
Description

High-content imaging (HCI) plates providing a soft culture substrate that mimics the aligned architecture of the native extracellular matrix, promoting structural and functional maturation of iPSC-derived cardiomyocytes and skeletal muscle cells; available in 96-well and 384-well formats.

7Cytostretcher™ Cell Stretching Instruments
CategoryInstrument
Description

Family of cell stretching systems (Cytostretcher and Cytostretcher-LV) that apply biomimetic mechanical strain to cells and tissues on bench-top, incubator, or optical microscope setups for in vitro mechanical stimulation studies.

8Pulse™ High-throughput Waveform and Video Analysis
CategoryData analytics platform (cloud software)
Description

Cloud-enabled data analytics platform combining machine learning, high-throughput data processing, and intuitive visualization tools to streamline functional analyses of complex biological datasets from human-relevant 3D and 2D models, including PhenoLearn™ deep learning and PhenoTox™ predictive safety pharmacology modules.

9ComboMat™ Cardiomyocyte Maturation Platform
CategoryMaturation platform / consumable system
Description

Combinatorial maturation platform that leverages NanoSurface™ technology, media factors, and a proprietary microRNA (miR) cocktail to synergistically advance the maturation of hiPSC-derived cardiomyocytes for predictive safety screening and disease modeling.

10MantaReady™ iPSC-Derived Skeletal Muscle Myoblasts
CategoryBiological product (cells)
Description

Quality-controlled, high-density cryopreserved iPSC-derived skeletal muscle myoblasts in wild type and isogenic DMD lines, paired with MantaReady Skeletal Muscle Medium to support 3D engineered muscle tissues in culture for months.

11MantaReady™ 3D Skeletal Muscle Tissue Media
CategoryBiological product (media)
Description

Proprietary serum-free media optimized for 3D engineered skeletal muscle tissue experiments, available as Primary and iPSC skeletal muscle media kits (differentiation + maintenance formulas) supporting long-term tissue culture.

12Celogics Celo.Cardiomyocytes (iPSC-derived cardiomyocytes)
CategoryBiological product (cells)
Description

High-quality iPSC-derived cardiomyocytes distributed via the Celogics joint venture between Curi Bio and NEXEL for use in drug discovery and safety testing by pharmaceutical and biotech customers.

13MYBPC3 HCM Cardiomyocytes (isogenic hypertrophic cardiomyopathy model)
CategoryDisease model cells
Description

Isogenic iPSC-derived cardiomyocyte line carrying the MYBPC3 mutation for hypertrophic cardiomyopathy disease modeling and drug discovery.

14Curi Engine™ Custom Research Services
CategoryContract research services
Description

Fee-for-service contract research leveraging the Curi Engine, including compound profiling/screening, assay/model development, AI-enabled phenotype screening studies, and customized endpoints for pharmaceutical customers across cardiac, skeletal muscle, and neuromuscular disease areas.

15Novoheart MyHeart™ hvCoC Integration with Pulse™ Analytics
CategoryCardiac organoid platform + analytics integration
Description

Integrated offering combining Novoheart's MyHeart™ hvCoC cardiac organoid chamber with Curi Bio's Pulse cloud analytics, enabling biopharmaceutical researchers to analyze cardiac organoid data for drug development and disease modeling.

16Battelle–Curi Bio Neuromuscular Junction (NMJ) Assay Technology
CategoryAssay technology / service
Description

Next-generation animal-free neuromuscular junction (NMJ) assay technology co-commercialized with Battelle, combining Curi Bio's 3D NMJ microphysiological systems with Battelle's GLP-ready infrastructure to replace mouse lethality bioassays for Botulinum neurotoxin potency testing and drug development.

17Neuromuscular Junction (NMJ) Model
CategoryDisease / tissue model
Description

iPSC-derived neuromuscular junction model used for animal-free BoNT potency testing and neuromuscular drug discovery.

18Duchenne Muscular Dystrophy (DMD) Disease Model
CategoryDisease model
Description

iPSC-derived 3D Duchenne muscular dystrophy (DMD) tissue model built from MantaReady isogenic DMD lines for translational and preclinical DMD research.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-20
Description

Strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. Combines Curi Bio's human-relevant 3D tissue microphysiological systems with Battelle's GLP-ready infrastructure to provide pharmaceutical researchers with functional, animal-free alternatives for BoNT potency testing and drug development. Positions to capitalize on FDA Non-Animal Models guidance and NIH's $150M commitment to human-relevant alternatives.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Fully acquired by Curi Bio to establish Curi Bio Co., Ltd. as wholly-owned South Korea subsidiary and APAC commercial/operational hub; integrates Quvit Bio's assets and team to reduce international logistics delays for cells, media, hardware, and consumables across South Korea, Japan, and China. Dr. Wonil Lee appointed VP of research and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

Strategic partnership announced via press release for combined muscle and cell therapy capabilities in drug discovery and regenerative medicine (referenced via press release title in Curi Bio news index).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-12-19
Description

Technology integration and joint commercialization: integration of Novoheart's MyHeart™ human ventricular cardiac organoid chamber (hvCoC, 'Human Heart-in-a-Jar') into Curi Bio's Pulse analytics platform. Enables Novoheart customers to analyze hvCoC data directly in Curi Bio's cloud-based Pulse platform, expanding predictive power of cardiac drug screening and disease modeling.

Strategic tierMinorTypeOthersAnnounced on2024-09-18
Description

Donated Mantarray™ instrument installed at MCRI in Melbourne, Australia with support from the Gillin Boys Foundation, to advance Duchenne muscular dystrophy (DMD) and other muscle disease research. Curi Bio, MCRI, and Gillin Boys Foundation entered into ongoing partnership.

6Gillin Boys Foundation
Strategic tierMinorTypeOthersAnnounced on2024-09-18
Description

Australian nonprofit that raised a quarter of a million dollars for muscle research in 18 months; co-partner with Curi Bio and MCRI to bring Mantarray technology to Melbourne for DMD and muscle disease research. Chris Gillin, who has Duchenne muscular dystrophy, is co-founder; a quote from Chris is engraved on the Mantarray instrument, which is coloured gold in honour of the partnership.

curibio.com
Strategic tierCoreTypeOthersAnnounced on2024-08-22
Description

Real estate partner; Curi Bio signed seven-year lease for 13,942 sq ft Class-A lab space at BioMed Realty's 201 Elliott Avenue West in Seattle, with grand opening April 3, 2025. BioMed Realty operates eight properties in the Seattle area.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-22
Description

MOU signed with DreamCIS for strategic collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay; partnership focuses on developing animal-free potency assays for Botulinum neurotoxin (Botox) using human-relevant 3D NMJ models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-23
Description

Long-standing research collaboration with University of Washington investigators, including Dr. Jeffrey S. Chamberlain (DMD therapies pioneer) and Dr. David L. Mack (neuromuscular diseases, iPSC, and whole-animal models). UW exclusively licenses Mantarray and ComboMat intellectual property to Curi Bio. Joint work on 3D DMD mouse and human models and Botulinum neurotoxin potency assays with Dr. Alec Smith and Dr. David Mack.

10U.S. National Institutes of Health (NIH) — NCATS and FDA
Strategic tierCoreTypeOthersAnnounced on2023-08-23
Description

Grant-funded collaborations via two SBIR grants totaling $4.4M from NIH (August 2023); supports 3D Duchenne muscular dystrophy (DMD) model and 3D neuromuscular junction model for potency assays, including applications for Botox. Project performed in conjunction with FDA and NCATS.

curibio.com
11NEXEL
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

Joint venture to form Celogics, a Seattle-based company developing and commercializing high-quality iPSC-derived cell products (Cardiosight®-S cardiomyocytes, Hepatosight®-S, Neurosight®-S) for drug discovery and safety testing. Celogics serves as major strategic entry for NEXEL into the US market (~50% of global stem cell market).

curibio.com
12Dana Solutions
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-23
Description

Curi Bio acquired Dana Solutions (July 2020), a pioneer in AI/ML for in vitro cell-based assays. Through the acquisition Curi gained access to PhenoLearn™ (deep learning for cell/tissue phenotypes), Pulse™ (contractility analysis), and PhenoTox™ (predictive safety pharmacology), and continues an FDA validation project previously funded via HESI.

curibio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ncardia develops and commercializes iPSC-derived cardiomyocytes, neurons, and other cell types for preclinical drug discovery and safety testing. It is one of Curi Bio's closest pure-play iPSC competitors, with overlapping pharma customer base and disease modeling applications.

TypeDirect peer
Description

FUJIFILM Cellular Dynamics is a long-established iPSC-derived cell provider (iCell cardiomyocytes, neurons, hepatocytes) serving pharmaceutical drug discovery and safety screening. It competes directly with Curi Bio's MantaReady myoblasts and Celogics cardiomyocyte product lines.

TypeEmerging player
Description

bit.bio uses a proprietary iPSC reprogramming technology (opti-ox) to produce defined human cell types at scale for research and drug discovery. It is an emerging iPSC peer with overlapping pharma customer use cases around disease modeling and safety pharmacology.

TypeDirect peer
Description

Novoheart develops human ventricular cardiac organoid chambers (hvCoC, "Human Heart-in-a-Jar") for cardiac drug development and disease modeling. It is both a direct peer in cardiac preclinical modeling and a commercial integration partner of Curi Bio's Pulse analytics platform.

TypeEmerging player
Description

InSphero provides 3D microtissue (organoid) models and assay platforms for drug discovery and safety testing. It overlaps with Curi Bio's 3D engineered tissue and disease modeling franchise, particularly in metabolic and liver applications.

TypeEmerging player
Description

Axol Bioscience supplies iPSC-derived cardiomyocytes, neurons, and other cell types for disease modeling and drug discovery. It competes with Curi Bio's MantaReady and Celogics iPSC product lines in research-grade disease modeling.

TypeBroad incumbent
Description

Charles River Laboratories is a global preclinical CRO with safety pharmacology, cell-based assay, and iPSC-derived services embedded in broader drug development contracts. It competes with Curi Bio on safety and efficacy screening, with the advantage of bundled enterprise deals.

TypeBroad incumbent
Description

Lonza is a global CDMO and cell therapy manufacturer with growing iPSC-derived cell products and preclinical services. It competes with Curi Bio across both cell product supply and broader preclinical services for large pharma.

TypeBroad incumbent
Description

Eurofins is a global testing and preclinical services group with cell-based assay, safety pharmacology, and bioanalytical capabilities. It competes with Curi Bio on outsourced preclinical testing, especially for European pharma customers.

TypeOthers
Description

StemCell Technologies supplies cell culture media, reagents, and primary/iPSC-derived cells supporting stem cell and organoid research. It is an enabling supplier/adjacent player rather than a direct competitor, often used alongside Curi Bio's platforms in pharma R&D workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curi Bio

Preclinical Drug Discovery Platformscuribio.com

Curi Bio is a Seattle-based preclinical biotech founded in 2015 that provides an integrated platform combining human iPSC-derived cell models, tissue biosystems, and AI/ML analytics to support drug safety, efficacy, and potency testing for global pharmaceutical R&D customers.

What Curi Bio does

Curi Bio (formerly NanoSurface Biomedical) is a Seattle-based preclinical biotechnology company founded in 2015 that has built the Curi Engine, an integrated platform combining human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic data analytics to support drug safety, efficacy, and potency testing for pharmaceutical R&D. The company's core technical architecture is three-pronged: proprietary human stem cell inputs (MantaReady skeletal muscle myoblasts in wild-type and isogenic DMD lines, ComboMat-matured hiPSC cardiomyocytes using a proprietary microRNA cocktail, plus Celogics iPSC-derived cell products); a portfolio of biosystem instruments (Mantarray for label-free, non-optical, magnetic 3D tissue contractility measurement of up to 24 parallel tissues, Nautilai/Nautilai Plus for voltage and calcium imaging, Stingray for tissue stimulation and maturation, Cytostretcher for biomimetic mechanical strain, and NanoSurface 96/384-well plates for structural maturation); and the Pulse cloud analytics platform with PhenoLearn (deep-learning phenotype modeling) and PhenoTox (FDA-validated predictive safety pharmacology) modules acquired from Dana Solutions.

Curi Bio's business model is anchored in enterprise sales to global pharmaceutical and biopharmaceutical R&D, with the company publicly stating that all of the top-10 global pharmaceutical companies are among its clients, customers, or partners. Revenue is generated through instrument and hardware sales (Mantarray, Nautilai, Cytostretcher), recurring consumables (NanoSurface plates, MantaReady cells and media, Celogics cardiomyocytes), fee-for-service Curi Engine contracts for compound profiling, assay/model development, and AI-enabled phenotypic screening, and subscription-based Pulse analytics. All pricing is quote-based and not publicly disclosed; commercial motion is sales-led with 'Request a Quote' CTAs, supplemented by strategic co-development and channel partnerships.

Curi Bio has executed a multi-year capital strategy combining equity ($6M Series A led by Dynamk Capital in March 2021, oversubscribed to $10M total in December 2021, and a $10M Series B led by Seoul-based DreamCIS in December 2025) with over $12M in cumulative non-dilutive NIH SBIR funding. Distribution and geographic reach are extended via the October 2021 Celogics joint venture with South Korea-based NEXEL for iPSC cell production, the January 2026 full acquisition of Quvit Bio establishing Curi Bio Co., Ltd. as an Asia-Pacific hub serving South Korea, Japan, and China, and co-commercialization partnerships with Battelle (Neuromuscular Junction assays, March 2026), Novoheart (Pulse + hvCoC integration, December 2024), and Cook MyoSite (April 2025). Proprietary technologies are protected by 19 patents, including exclusive University of Washington licenses for Mantarray and ComboMat, and the company was ranked #123 (and #18 of 70 life sciences companies) on Deloitte's 2024 Technology Fast 500.

Curi Bio firmographics

Firmographics
Name
Curi Bio
Legal name
Curi Bio, Inc.
Website
https://curibio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Curi Bio is a Seattle-based preclinical biotech founded in 2015 that provides an integrated platform combining human iPSC-derived cell models, tissue biosystems, and AI/ML analytics to support drug safety, efficacy, and potency testing for global pharmaceutical R&D customers.
Ownership category
akta.pro rank

Curi Bio industry classification

Industry
Product category
Preclinical Drug Discovery Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • IPSC-derived tissue models
  • Preclinical drug discovery
  • 3D engineered tissues
  • Contractility analysis platforms
  • AI-enabled phenotypic screening

Where Curi Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Curi Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Instrument & Hardware Sales: One-time and capital sale of bioscience instruments and platforms including Mantarray, Nautilai, Nautilai Plus, Stingray, and Cytostretcher, paired with multiwell consumable plates and ongoing service contracts.
  2. Consumables & Biological Products: Recurring revenue from cells, media, and plates (NanoSurface 96/384-well plates, MantaReady myoblasts, MantaReady Skeletal Muscle Media, cardiac media, metabolic media, Celogics Celo.Cardiomyocytes) sold as standalone catalog products or as kits.
  3. Curi Engine™ Custom Research Services: Fee-for-service contracts and partnerships leveraging the Curi Engine, including compound profiling/screening, assay/model development, A.I.-enabled phenotype screening studies, and customized endpoints for pharmaceutical customers.
  4. Software / Data Analytics (Pulse): Cloud-based Pulse analytics platform offered for high-throughput waveform and video analysis of contractility datasets, with integrations to instruments like Novoheart's hvCoC; positioned as turnkey analytics pipeline.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing for instruments, consumables, services, and analytics

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Curi Bio product offering

Product offering

Core offering

Curi Bio develops, manufactures, and sells an integrated preclinical drug discovery platform (the Curi Engine™) that combines human iPSC-derived cell and disease models (cardiac, skeletal muscle, neuromuscular), proprietary 3D tissue biosystems (Mantarray contractility, NanoSurface plates, ComboMat maturation, Stingray, Nautilai, Cytostretcher), biological consumables (MantaReady cells and media, Celogics Celo.Cardiomyocytes, MYBPC3 HCM lines), and the Pulse™ cloud AI/ML analytics platform. The company also offers Curi Engine™ fee-for-service contract research for compound screening, assay development, and phenotypic safety/efficacy/potency studies to pharmaceutical and biotech customers.

Differentiator

Problem solved

Functional benefit

Brands

  • Mantarray: Proprietary label-free, non-optical, electromagnetic platform for parallel analysis of up to 24 3D engineered muscle tissues (EMTs) for drug discovery.
  • Mantarray Mini Plates
  • Nautilai
  • Nautilai Plus
  • Stingray
  • NanoSurface
  • Cytostretcher
  • ComboMat
  • Pulse
  • MantaReady
  • Celogics
  • Curi Engine

Products and services

  • Mantarray™ 3D Tissue Contractility Analysis Platform Proprietary biosystem platform that uses a label-free, non-optical, electromagnetic measurement system to directly assess contractility of up to 24 parallel iPSC-derived 3D engineered muscle tissues simultaneously, enabling discovery, safety, and efficacy testing of new therapeutics across cardiac and skeletal muscle applications. Sold to pharmaceutical, biotech, and academic customers.
  • Mantarray Mini Plates Latest addition to the 3D Engineered Tissue Ecosystem; reduces biological material requirements for 3D engineered tissues while maintaining full compatibility with Mantarray and Nautilai platforms, addressing cell sourcing challenges and enabling cost-effective higher-throughput studies.
  • Nautilai™ Voltage & Calcium Imaging Biosystem platform for voltage and calcium imaging of 3D engineered tissues, enabling fluorescence-based functional analyses of iPSC-derived cardiac and skeletal muscle constructs.
  • Nautilai Plus™ 3D Tissue Contractility and Fluorescence at Scale Scales 3D tissue contractility and fluorescence imaging capabilities, extending the Nautilai platform for higher-throughput functional analyses of engineered tissues.
  • Stingray™ Stimulation and Maturation of 3D Engineered Tissues Biosystem platform for stimulation and maturation of 3D engineered tissues, enabling electrical/mechanical conditioning to advance translational research with iPSC-derived tissues.
  • NanoSurface™ Plates (96-well and 384-well) High-content imaging (HCI) plates providing a soft culture substrate that mimics the aligned architecture of the native extracellular matrix, promoting structural and functional maturation of iPSC-derived cardiomyocytes and skeletal muscle cells; available in 96-well and 384-well formats.
  • Cytostretcher™ Cell Stretching Instruments Family of cell stretching systems (Cytostretcher and Cytostretcher-LV) that apply biomimetic mechanical strain to cells and tissues on bench-top, incubator, or optical microscope setups for in vitro mechanical stimulation studies.
  • Pulse™ High-throughput Waveform and Video Analysis Cloud-enabled data analytics platform combining machine learning, high-throughput data processing, and intuitive visualization tools to streamline functional analyses of complex biological datasets from human-relevant 3D and 2D models, including PhenoLearn™ deep learning and PhenoTox™ predictive safety pharmacology modules.
  • ComboMat™ Cardiomyocyte Maturation Platform Combinatorial maturation platform that leverages NanoSurface™ technology, media factors, and a proprietary microRNA (miR) cocktail to synergistically advance the maturation of hiPSC-derived cardiomyocytes for predictive safety screening and disease modeling.
  • MantaReady™ iPSC-Derived Skeletal Muscle Myoblasts Quality-controlled, high-density cryopreserved iPSC-derived skeletal muscle myoblasts in wild type and isogenic DMD lines, paired with MantaReady Skeletal Muscle Medium to support 3D engineered muscle tissues in culture for months.
  • MantaReady™ 3D Skeletal Muscle Tissue Media Proprietary serum-free media optimized for 3D engineered skeletal muscle tissue experiments, available as Primary and iPSC skeletal muscle media kits (differentiation + maintenance formulas) supporting long-term tissue culture.
  • Celogics Celo.Cardiomyocytes (iPSC-derived cardiomyocytes) High-quality iPSC-derived cardiomyocytes distributed via the Celogics joint venture between Curi Bio and NEXEL for use in drug discovery and safety testing by pharmaceutical and biotech customers.
  • MYBPC3 HCM Cardiomyocytes (isogenic hypertrophic cardiomyopathy model) Isogenic iPSC-derived cardiomyocyte line carrying the MYBPC3 mutation for hypertrophic cardiomyopathy disease modeling and drug discovery.
  • Curi Engine™ Custom Research Services Fee-for-service contract research leveraging the Curi Engine, including compound profiling/screening, assay/model development, AI-enabled phenotype screening studies, and customized endpoints for pharmaceutical customers across cardiac, skeletal muscle, and neuromuscular disease areas.
  • Novoheart MyHeart™ hvCoC Integration with Pulse™ Analytics Integrated offering combining Novoheart's MyHeart™ hvCoC cardiac organoid chamber with Curi Bio's Pulse cloud analytics, enabling biopharmaceutical researchers to analyze cardiac organoid data for drug development and disease modeling.
  • Battelle–Curi Bio Neuromuscular Junction (NMJ) Assay Technology Next-generation animal-free neuromuscular junction (NMJ) assay technology co-commercialized with Battelle, combining Curi Bio's 3D NMJ microphysiological systems with Battelle's GLP-ready infrastructure to replace mouse lethality bioassays for Botulinum neurotoxin potency testing and drug development.
  • Neuromuscular Junction (NMJ) Model iPSC-derived neuromuscular junction model used for animal-free BoNT potency testing and neuromuscular drug discovery.
  • Duchenne Muscular Dystrophy (DMD) Disease Model iPSC-derived 3D Duchenne muscular dystrophy (DMD) tissue model built from MantaReady isogenic DMD lines for translational and preclinical DMD research.

Quantifiable outcome

  • Selected for 2024 Deloitte Technology Fast 500 with rank #123 (#18 of 70 life sciences companies), based on percentage fiscal year revenue growth 2020–2023.
  • +4 more outcomes

Companies that use Curi Bio

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Curi Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature8 records

Curi Bio partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

  • BattelleflagshipStrategic or Co-development Partner · 20 March 2026Strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. Combines Curi Bio's human-relevant 3D tissue microphysiological systems with Battelle's GLP-ready infrastructure to provide pharmaceutical researchers with functional, animal-free alternatives for BoNT potency testing and drug development. Positions to capitalize on FDA Non-Animal Models guidance and NIH's $150M commitment to human-relevant alternatives.
  • Quvit BiocoreStrategic or Co-development Partner · 12 January 2026Fully acquired by Curi Bio to establish Curi Bio Co., Ltd. as wholly-owned South Korea subsidiary and APAC commercial/operational hub; integrates Quvit Bio's assets and team to reduce international logistics delays for cells, media, hardware, and consumables across South Korea, Japan, and China. Dr. Wonil Lee appointed VP of research and commercialization.
  • Cook MyoSitecoreStrategic or Co-development Partner · 30 April 2025Strategic partnership announced via press release for combined muscle and cell therapy capabilities in drug discovery and regenerative medicine (referenced via press release title in Curi Bio news index).
  • NovoheartcoreTechnology or Integration · 19 December 2024Technology integration and joint commercialization: integration of Novoheart's MyHeart™ human ventricular cardiac organoid chamber (hvCoC, 'Human Heart-in-a-Jar') into Curi Bio's Pulse analytics platform. Enables Novoheart customers to analyze hvCoC data directly in Curi Bio's cloud-based Pulse platform, expanding predictive power of cardiac drug screening and disease modeling.
  • Murdoch Children's Research Institute (MCRI)minorOthers · 18 September 2024Donated Mantarray™ instrument installed at MCRI in Melbourne, Australia with support from the Gillin Boys Foundation, to advance Duchenne muscular dystrophy (DMD) and other muscle disease research. Curi Bio, MCRI, and Gillin Boys Foundation entered into ongoing partnership.
  • Gillin Boys FoundationminorOthers · 18 September 2024Australian nonprofit that raised a quarter of a million dollars for muscle research in 18 months; co-partner with Curi Bio and MCRI to bring Mantarray technology to Melbourne for DMD and muscle disease research. Chris Gillin, who has Duchenne muscular dystrophy, is co-founder; a quote from Chris is engraved on the Mantarray instrument, which is coloured gold in honour of the partnership.
  • BioMed RealtycoreOthers · 22 August 2024Real estate partner; Curi Bio signed seven-year lease for 13,942 sq ft Class-A lab space at BioMed Realty's 201 Elliott Avenue West in Seattle, with grand opening April 3, 2025. BioMed Realty operates eight properties in the Seattle area.
  • GenetoxcoreStrategic or Co-development Partner · 22 February 2024MOU signed with DreamCIS for strategic collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay; partnership focuses on developing animal-free potency assays for Botulinum neurotoxin (Botox) using human-relevant 3D NMJ models.
  • University of Washington (Dr. Jeffrey S. Chamberlain and Dr. David L. Mack)coreStrategic or Co-development Partner · 23 August 2023Long-standing research collaboration with University of Washington investigators, including Dr. Jeffrey S. Chamberlain (DMD therapies pioneer) and Dr. David L. Mack (neuromuscular diseases, iPSC, and whole-animal models). UW exclusively licenses Mantarray and ComboMat intellectual property to Curi Bio. Joint work on 3D DMD mouse and human models and Botulinum neurotoxin potency assays with Dr. Alec Smith and Dr. David Mack.
  • U.S. National Institutes of Health (NIH) — NCATS and FDAcoreOthers · 23 August 2023Grant-funded collaborations via two SBIR grants totaling $4.4M from NIH (August 2023); supports 3D Duchenne muscular dystrophy (DMD) model and 3D neuromuscular junction model for potency assays, including applications for Botox. Project performed in conjunction with FDA and NCATS.
  • NEXELflagshipStrategic or Co-development Partner · 26 October 2021Joint venture to form Celogics, a Seattle-based company developing and commercializing high-quality iPSC-derived cell products (Cardiosight®-S cardiomyocytes, Hepatosight®-S, Neurosight®-S) for drug discovery and safety testing. Celogics serves as major strategic entry for NEXEL into the US market (~50% of global stem cell market).
  • Dana SolutionscoreStrategic or Co-development Partner · 23 July 2020Curi Bio acquired Dana Solutions (July 2020), a pioneer in AI/ML for in vitro cell-based assays. Through the acquisition Curi gained access to PhenoLearn™ (deep learning for cell/tissue phenotypes), Pulse™ (contractility analysis), and PhenoTox™ (predictive safety pharmacology), and continues an FDA validation project previously funded via HESI.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Curi Bio competitors and assessment

Company assessment

Direct peers

  • Ncardia: Ncardia develops and commercializes iPSC-derived cardiomyocytes, neurons, and other cell types for preclinical drug discovery and safety testing. It is one of Curi Bio's closest pure-play iPSC competitors, with overlapping pharma customer base and disease modeling applications.
  • FUJIFILM Cellular Dynamics: FUJIFILM Cellular Dynamics is a long-established iPSC-derived cell provider (iCell cardiomyocytes, neurons, hepatocytes) serving pharmaceutical drug discovery and safety screening. It competes directly with Curi Bio's MantaReady myoblasts and Celogics cardiomyocyte product lines.
  • Novoheart: Novoheart develops human ventricular cardiac organoid chambers (hvCoC, "Human Heart-in-a-Jar") for cardiac drug development and disease modeling. It is both a direct peer in cardiac preclinical modeling and a commercial integration partner of Curi Bio's Pulse analytics platform.

Emerging players

  • bit.bio: bit.bio uses a proprietary iPSC reprogramming technology (opti-ox) to produce defined human cell types at scale for research and drug discovery. It is an emerging iPSC peer with overlapping pharma customer use cases around disease modeling and safety pharmacology.
  • InSphero: InSphero provides 3D microtissue (organoid) models and assay platforms for drug discovery and safety testing. It overlaps with Curi Bio's 3D engineered tissue and disease modeling franchise, particularly in metabolic and liver applications.
  • Axol Bioscience: Axol Bioscience supplies iPSC-derived cardiomyocytes, neurons, and other cell types for disease modeling and drug discovery. It competes with Curi Bio's MantaReady and Celogics iPSC product lines in research-grade disease modeling.

Broad incumbents

  • Charles River Laboratories: Charles River Laboratories is a global preclinical CRO with safety pharmacology, cell-based assay, and iPSC-derived services embedded in broader drug development contracts. It competes with Curi Bio on safety and efficacy screening, with the advantage of bundled enterprise deals.
  • Lonza: Lonza is a global CDMO and cell therapy manufacturer with growing iPSC-derived cell products and preclinical services. It competes with Curi Bio across both cell product supply and broader preclinical services for large pharma.
  • Eurofins Scientific: Eurofins is a global testing and preclinical services group with cell-based assay, safety pharmacology, and bioanalytical capabilities. It competes with Curi Bio on outsourced preclinical testing, especially for European pharma customers.

Others

  • StemCell Technologies: StemCell Technologies supplies cell culture media, reagents, and primary/iPSC-derived cells supporting stem cell and organoid research. It is an enabling supplier/adjacent player rather than a direct competitor, often used alongside Curi Bio's platforms in pharma R&D workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Curi Bio social profiles

Digital presence

Curi Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curi Bio leadership team

Management profile

Number of profiles

Profiles7 records

Curi Bio subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Curi Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curi Bio M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curi Bio

What does Curi Bio do?

Curi Bio develops, manufactures, and sells an integrated preclinical drug discovery platform (the Curi Engine™) that combines human iPSC-derived cell and disease models (cardiac, skeletal muscle, neuromuscular), proprietary 3D tissue biosystems (Mantarray contractility, NanoSurface plates, ComboMat maturation, Stingray, Nautilai, Cytostretcher), biological consumables (MantaReady cells and media, Celogics Celo.Cardiomyocytes, MYBPC3 HCM lines), and the Pulse™ cloud AI/ML analytics platform. The company also offers Curi Engine™ fee-for-service contract research for compound screening, assay development, and phenotypic safety/efficacy/potency studies to pharmaceutical and biotech customers.

Is Curi Bio a public or private company?

Curi Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Curi Bio founded?

Curi Bio was founded in 2015. It employs 51 to 100 people.

Where is Curi Bio based?

Curi Bio is headquartered in Seattle, United States, in the North America region.

How does Curi Bio make money?

Four revenue lines are on record. Instrument & Hardware Sales are the primary driver. The others are consumables & Biological Products, curi Engine™ Custom Research Services and software / Data Analytics (Pulse).

Who are Curi Bio's main competitors?

Direct peers on record are Ncardia, FUJIFILM Cellular Dynamics and Novoheart. Emerging players are bit.bio, InSphero and Axol Bioscience. Broad incumbents are Charles River Laboratories, Lonza and Eurofins Scientific. StemCell Technologies is listed as an others.

Does Curi Bio have an API?

No public API is recorded for Curi Bio.

What industry is Curi Bio in?

Curi Bio's product category is Preclinical Drug Discovery Platforms. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCuri Bio Launches the Curiverse™ at MPS 2026: The Industry’s First Closed-Loop Ecosystem for Industrial-Scale, Human-Relevant Drug DiscoveryCuri Bio unveiled Curiverse at MPS 2026, an integrated ecosystem for industrial-scale drug discovery using iPSC-derived cells, automated systems, and data analytics. The platform scales to 96-well throughput, introducing Nautilai Plus and Stingray for high-throughput screening. It aims to replace animal models with human-relevant NAMs.PR NewswireAccelerate Predictive Drug Discovery with Scalable 3D Human Functional Models, Upcoming Webinar Hosted by XtalksXtalks is hosting a free webinar on May 26, 2026, featuring Nicholas Geisse, CEO of Curi Bio, to discuss how laboratories can scale 3D human-functional models for predictive drug discovery. The webinar will focus on Curi Bio's ecosystem approach combining assay-ready cells, automated hardware, and quantitative analysis to advance Non-Animal Models (NAMs) from research to regulatory implementation. Attendees will also receive an exclusive preview of upcoming 96-well functional platforms designed for industrial-scale drug discovery applications.BioSpaceCuri Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular PharmacologyCuri Bio and Battelle announced a strategic partnership to commercialize next-generation Neuromuscular Junction assay technology, combining Curi Bio's human-relevant 3D tissue microphysiological systems with Battelle's GLP-ready infrastructure. The partnership aims to replace traditional animal-based bioassays with reproducible human-tissue models for BoNT potency testing and drug development applications. The collaboration positions itself to capitalize on shifting regulatory support, including FDA's new Non-Animal Models guidance and NIH's $150 million commitment to human-relevant alternatives.Business Wire BlogCuri Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular PharmacologyCuri Bio and Battelle announced a strategic partnership to commercialize Neuromuscular Junction assay technology, combining Curi Bio's human-relevant 3D tissue microphysiological systems with Battelle's GLP-ready infrastructure and regulatory expertise. The collaboration aims to replace traditional animal-based pharmacology methods with scalable, human-relevant alternatives for drug substance and medical countermeasure development pipelines. The partnership aligns with FDA's Non-Animal Models guidance and NIH's $150M commitment to human-relevant alternatives, positioning both companies to set a new gold standard for potency testing.MorningstarCuri Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular PharmacologyCuri Bio and Battelle announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology, combining Curi Bio's human-relevant 3D tissue models with Battelle's GLP-ready infrastructure. The collaboration aims to provide pharmaceutical researchers with functional, animal-free alternatives to traditional pharmacology methods for BoNT potency testing. The partnership is positioned to benefit from recent regulatory tailwinds including FDA's Non-Animal Models guidance and NIH's $150M commitment to human-relevant alternatives.Pulse 2.0Curi Bio Establishes Asia-Pacific Hub Following Full Acquisition Of South Korea’s Quvit BioCuri Bio has established Curi Bio Co., Ltd., a wholly owned subsidiary in South Korea, following its full acquisition of Quvit Bio, creating an Asia-Pacific commercial and operational hub. The new entity is "day-1 ready" with sales, R&D, and operational capabilities to serve customers across South Korea, Japan, and China, integrating Quvit Bio's assets and team to reduce international logistics delays for cell, media, hardware, and consumables deliveries. Dr. Wonil Lee has been appointed vice president of research and commercialization to lead the regional operations.CuribioCuri Bio Launches Asia-Pacific Hub, Delivering Greater Support to its Growing APAC Business — Curi BioCuri Bio has formally established Curi Bio Co., Ltd., a wholly-owned subsidiary in South Korea, following the full acquisition of Quvit Bio to serve as its Asia-Pacific commercial and operational hub. The new subsidiary will provide localized technical and sales support across South Korea, Japan, and China while delivering cells, media, hardware, and consumables products with reduced international logistics delays. This expansion signals Curi Bio's commitment to accelerating its global strategy and expanding access to its NAM technology throughout the APAC region.Pulse 2.0Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical PlatformsCuri Bio, a Seattle-based preclinical drug discovery platform company, has closed a $10 million Series B funding round led by Seoul-based contract research organization DreamCIS. The capital will fund expansion of the company's iPSC-derived cell platforms and 3D biosystems designed to provide more predictive human-relevant data than traditional animal and 2D models during early drug development. The investment deepens an existing strategic partnership between the two companies and is expected to support global expansion into broader clinical development workflows.FinSMEsCuri Bio Raises $10M in Series B FundingCuri Bio, a Seattle-based drug discovery company, raised $10M in Series B funding led by DreamCIS. The company will use the funds to accelerate development of platforms for cardiac, skeletal muscle, metabolic, smooth muscle, and neuromuscular diseases and expand its global commercial reach.KoreatimesJohns Hopkins to host US-Korea biotechnology forum in SongdoJohns Hopkins University will host the Global Biotechnology Innovation Summit in Songdo, Incheon, Korea, on Thursday, bringing together government agencies, companies, and scholars from Korea and the United States to explore bilateral cooperation in the bio industry. The forum will cover topics including organoids, AI-based drug development, biomanufacturing, and investment strategies for bio startups, with participation from faculty at Johns Hopkins, Harvard, and Cambridge universities. Industry leaders from Samsung Biologics, DreamCIS, Curi Bio, and Celltrion will present their latest services, while Korean government agencies aim to position Songdo as a global bio innovation hub.